FDA shortage, label and recall data -- live and queryable by any AI: gateway.pipeworx.io
FDA shortage, label and recall data -- live and queryable by any AI: gateway.pipeworx.io
Armed Forces Institute of Pathology / Public domain InnoCare Pharma has dosed the first patient in a Phase III trial in China comparing its experimental leukemia drug mesutoclax plus azacitidine with venetoclax plus…
Armed Forces Institute of Pathology / Public domain InnoCare Pharma has dosed the first patient in a Phase III trial in China comparing its experimental leukemia drug mesutoclax plus azacitidine with venetoclax plus…
https://www.biorxiv.org/content/10.64898/2026.11.04.764360v1
https://www.biorxiv.org/content/10.64898/2026.11.04.764360v1
https://www.stocktitan.net/news/APVO/aptevo-achieves-key-clinical-development-objective-significantly-iv41i7mx8x54.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/APVO/aptevo-achieves-key-clinical-development-objective-significantly-iv41i7mx8x54.html?utm_source=stocktitan-bluesky&utm_medium=social
See the data here: https://bit.ly/4A1K1Gb
See the data here: https://bit.ly/4A1K1Gb
On October 26, 2026, Aptevo Therapeutics Inc. issued a press release announcing ten patients with newly diagnosed acute myeloid leukemia (AML) have advanced to allogeneic stem cell transplant following treatment with mipletamig in combination with venetoclax and azacitidine.
On October 26, 2026, Aptevo Therapeutics Inc. issued a press release announcing ten patients with newly diagnosed acute myeloid leukemia (AML) have advanced to allogeneic stem cell transplant following treatment with mipletamig in combination with venetoclax and azacitidine.
https://www.stocktitan.net/news/APVO/aptevo-reports-mipletamig-combination-therapy-enabled-21-of-z0rxkzoymu4o.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/APVO/aptevo-reports-mipletamig-combination-therapy-enabled-21-of-z0rxkzoymu4o.html?utm_source=stocktitan-bluesky&utm_medium=social
We show that stabilizing PP2A-B56α overcome venetoclax–azacitidine resistance in acute myeloid leukemia by targeting mitochondrial metabolism.
Great collaboration with teams in Navarra and the University of Michigan!
insight.jci.org/articles/vie...
We show that stabilizing PP2A-B56α overcome venetoclax–azacitidine resistance in acute myeloid leukemia by targeting mitochondrial metabolism.
Great collaboration with teams in Navarra and the University of Michigan!
insight.jci.org/articles/vie...
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
Read more: www.onclive.com/view/oral-az...
Read more: www.onclive.com/view/oral-az...
This week, hear from Prof Thomas Milne as he discusses his latest article in Blood on gene regulation in KMT2A rearranged acute lymphoblastic #leukaemia.
#BloodCancerResearch #AcademicSky 🧪
This week, hear from Prof Thomas Milne as he discusses his latest article in Blood on gene regulation in KMT2A rearranged acute lymphoblastic #leukaemia.
#BloodCancerResearch #AcademicSky 🧪